Epidemiology of severe myoclonic epilepsy of infancy
1Department of Medical and Surgical Neurology, Texas Tech University Health Sciences Center, Lubbock 79430.
Abstract:
Severe myoclonic epilepsy of infancy (SMEI) is a newly recognized epileptic syndrome. It is characterized by multiple febrile seizures, often prolonged, subsequent development of uncontrollable mixed-myoclonic seizures, and, eventually, psychomotor retardation. Drugs for myoclonic epilepsy--valproate (VPA), the suximides, and the benzodiazepines--have been shown to be useful in SMEI. Among children with seizures in the National Institute of Neurological and Communicative Disorders and Stroke Collaborative Perinatal Project (NCPP), one individual with SMEI was identified. This finding from the NCPP suggests that the incidence of SMEI is approximately 1 in 40,000 children. Such an incidence is supported by observations at the Texas Tech University Health Sciences Center.
Insights
Severe myoclonic epilepsy of infancy (SMEI) is a rare epilepsy syndrome. Research suggests its incidence is approximately 1 in 40,000 children, with certain medications showing promise for treatment.
Area of Science:
- Neurology
- Pediatric Neurology
- Epilepsy Research
Background:
- Severe myoclonic epilepsy of infancy (SMEI) is an emerging epileptic syndrome.
- It presents with prolonged febrile seizures, progressing to intractable mixed-myoclonic seizures and psychomotor retardation.
- Current treatments for myoclonic epilepsy, including valproate, suximides, and benzodiazepines, are being investigated for SMEI.
Purpose of the Study:
- To identify the incidence of Severe Myoclonic Epilepsy of Infancy (SMEI) within a large cohort.
- To provide an updated epidemiological understanding of this rare epilepsy syndrome.
Main Methods:
- Analysis of seizure data from the National Institute of Neurological and Communicative Disorders and Stroke Collaborative Perinatal Project (NCPP).
- Identification of individuals diagnosed with SMEI within the NCPP cohort.
Main Results:
- One case of SMEI was identified in the NCPP cohort.
- This finding suggests an incidence rate of approximately 1 in 40,000 children for SMEI.
- This incidence estimate is corroborated by data from Texas Tech University Health Sciences Center.
Conclusions:
- The incidence of Severe Myoclonic Epilepsy of Infancy (SMEI) is estimated to be around 1 in 40,000 children.
- Further research and clinical observation are supported by these epidemiological findings.
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Encephalitis l: Introduction
Seizures l: Introduction
Seizures ll: Types
Epilepsy ll: Types


